1. Home
  2. XYF vs RZLT Comparison

XYF vs RZLT Comparison

Compare XYF & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XYF

X Financial each representing six

HOLD

Current Price

$6.63

Market Cap

260.6M

Sector

Finance

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$2.00

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XYF
RZLT
Founded
2014
2010
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
260.6M
1.0B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
XYF
RZLT
Price
$6.63
$2.00
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$12.33
AVG Volume (30 Days)
243.8K
9.8M
Earning Date
11-20-2025
11-06-2025
Dividend Yield
7.87%
N/A
EPS Growth
49.84
N/A
EPS
5.72
N/A
Revenue
$1,106,908,607.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.24
N/A
Revenue Growth
47.14
N/A
52 Week Low
$6.47
$1.07
52 Week High
$20.36
$11.46

Technical Indicators

Market Signals
Indicator
XYF
RZLT
Relative Strength Index (RSI) 26.86 25.51
Support Level $6.68 $1.07
Resistance Level $7.28 $1.85
Average True Range (ATR) 0.39 0.64
MACD 0.15 -0.98
Stochastic Oscillator 15.04 10.00

Price Performance

Historical Comparison
XYF
RZLT

About XYF X Financial each representing six

X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: